Search
Sodium citrate
go.drugbank.com/drugs/DB09154ApprovedInvestigationalIt has been indicated for the treatment of metabolic acidosis. … Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works by neutralizing excess acid in the blood and urine.
Mixtures: Citrocarbonate Eff Pws, As 3Octinoxate
go.drugbank.com/drugs/DB09496ApprovedInvestigationalIt was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun.
Mixtures: Cler Zinck 45 SPF Sunblock, SPF20/PA plusProducts: High Protection Sun Air Spray SPF50 PA, Placenta EX Day Spf30 Pa Plus PlusAmbrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalIt is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. … As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.
Dimethicone 410
go.drugbank.com/drugs/DB14005Approved[L2162] The name dimethicone has a lot of nomenclature inconsistencies as it is used to refer to common names, generic names, trade names or even for the listing of mixtures. … [L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%.
Products: Gas Relief Ultra StrengthOctasulfur
go.drugbank.com/drugs/DB09353ApprovedIt has been also used for acne.
Mixtures: Sulfatol 10-4 Cleansing pads, Avar Cleansing PadsAceclidine
go.drugbank.com/drugs/DB13262ApprovedAceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274283] As compared to less selective miotics, like [pilocarpine], aceclidine's relative stimulation of the ciliary muscle is significantly less and, as such, induces far less myopic shift, lens thickening
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities such as hypertension, diabetes, and depression.
Agomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalAgomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. … The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigational[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. … Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].
Mixtures: PMS-dopazide 15 Tab, PMS-dopazide-25 TabFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn. … Some clinical data has suggested that the clinically recommended dose of 250mg was too low.